Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry’s decline of 2.2%. The ...

Markets around the world, including the US and China, all took a big drop during the uncertainty surrounding President ...

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Royalty Pharma will provide up to $1.25 billion in exchange for a synthetic royalty on annual worldwide net sales of daraxonrasib (and zoldonrasib if approved in an overlapping daraxonrasib indication ...

Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options begin trading this week, for the February 2026 expiration. One of the key inputs that goes into the price an option buyer is willing ...

Today, we talk about Gilead’s historic approval for HIV prevention, see a U.K. agency reject Alzheimer’s drugs over cost concerns, and hear crickets from the FDA regarding AI-driven medical ...

Pharmalittle: We’re reading about FDA forcing out top gene therapy regulator, Gilead’s HIV challenges and more ...

Gilead Sciences, Inc. GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV. The regulatory body approved lenacapavir, under the ...

吉利德科学公司 (Gilead Sciences) (NASDAQ: GILD )是一家年收入达287亿美元、毛利率高达78%的知名生物技术公司，其可注射HIV-1衣壳抑制剂Yeztugo (lenacapavir)获得FDA批准用于暴露前预防 (PrEP)。该药物成为美国首个也是唯一一个半年注射一次的HIV预防选择，适用于体重至少35公斤的成人和青少年。